---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-066623"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-05-27T12:50:46+00:00"
generated_at: "2026-05-27T12:55:18.932910+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma announces antiviral program targeting Hantavirus and Ebola outbreaks

## Summary
- Novel dual-strike combination agent exploits host nucleotide depletion and forced incorporation to halt viral replication.
- Non-clinical development advancing in BSL-3/4 labs; plans to engage CDC, NAFDAC, and AMA for fast-track development.
- Company scaling chemical manufacturing to enable immediate supply and potential stockpiling for health agencies.
- Former CDC head Dr. Robert Redfield appointed CMO; CEO Iain Dukes highlights rapid response capabilities.

## SEC filing metadata
- accession: 0001104659-26-066623
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-05-27T12:50:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926066623/0001104659-26-066623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926066623/tm2615712d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-066623
- JSON: https://secwatch.observer/filing/0001104659-26-066623.json
- Plain text: https://secwatch.observer/filing/0001104659-26-066623.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.